Two Important Sexual Health Topics: Chlamydia and HIV Infections and VACCINE Research Against Them

Sexual behavior is a complex activity affecting every aspect of human life. Besides their effects on health, risky sexual behaviors also negatively affect family and social relationships. Unsafe sex is the second leading cause worldwide of years of life lost due to vulnerability (carelessness, weakness). Teaching appropriate behaviors in place of risky sexual behaviors and implementing preventive measures with reliable tools are very important for healthy living.
Risky sexual behavior is the transmission, through active contact, of microorganisms that cause sexually transmitted infections.
As a result of risky sexual behavior, many diseases, ranging from simple infections to fatal illnesses, can be transmitted to another person. Similarly, risky sexual behaviors, particularly through HPV (Human Papilloma Virus), can lead to head and neck cancers, cervical (neck of the womb), vaginal, anal, penile cancers, as a result of the chronic infection that develops after sexual transmission of HPV. Entirely unsafe sex is the second leading cause of the global disease burden worldwide (ahead of smoking, alcohol and high blood pressure) (% 6,3).
Among sexually transmitted diseases, particularly AIDS and Chlamydia Disease are important. AIDS is one of the most dangerous sexually transmitted diseases and is spread by HIV. Chlamydia is another important sexually transmitted disease, spread by the bacterium Chlamydia trachomatis.
Chlamydia infection
Chlamydia is the most commonly reported disease in the United States and is among the most common of all sexually transmitted diseases.
Chlamydia infection usually causes no symptoms in women. A prolonged, untreated infection can cause pelvic inflammatory disease (PID), a leading cause of infertility, ectopic pregnancy and prolonged lower abdominal pain. As with other sexually transmitted infections, chlamydial infection facilitates HIV transmission. In addition, pregnant women infected with chlamydia can pass the infection to their babies during delivery, rarely causing blindness and pneumonia in the infant. Although the number of reported chlamydia infection cases among men appears to be half that among women, data from 2000-2017 show a continuing increase among men.
Most chlamydia cases reported in women and men in 2017 were among those aged 15-44 (%97.4 of women, %94.2 of men). In this age group, chlamydia is most common in both sexes, particularly between the ages of 20-24.
Because of the high disease burden and infection-related risks, annual chlamydia screening is recommended for all sexually active women younger than 25 and for women older than 25 who have an increased risk of infection (for example, those with new or multiple sex partners).
The newly developed chlamydia vaccine
Despite national screening programs and antibiotic treatments, chlamydia remains the most common sexually transmitted bacterial infection worldwide. In the fight against chlamydia, no vaccine against genital chlamydia had previously been tested in clinical trials. However, a promising development in this area occurred recently.
A phase-1 clinical study conducted for this purpose evaluated the safety and immunogenicity of a new chlamydia vaccine (vaccine candidate) based on a recombinant protein subunit (CTH522). The chlamydia vaccine successfully completed its first phase in this study (source 1).
HIV
Since the beginning of the epidemic, HIV has affected 75 million people worldwide, and approximately 32 million have died from AIDS (immune deficiency syndrome) resulting from HIV infection. Nearly 40 million people worldwide are infected with HIV. Worldwide, the proportion of people aged 15-49 who are infected with HIV is close to %1. In Africa, approximately one in every 25 people has HIV (%3.9).
In Europe and America, those most affected by HIV are men who have sex with men or transgender people. In the United States, gay and bisexual men account for an estimated % 4 of the population but two-thirds of new HIV diagnoses. Among transgender women, % 14 live with HIV. Women and girls account for approximately %60 of people with HIV in eastern and southern Africa.
Related topic: Cancers and other diseases associated with HIV infection (in detail)
HIV vaccine
Recently, the US National Institutes of Health (NIH) and its partners announced plans to test the efficacy of an HIV vaccine in a phase-3 study (source 2). The study is being conducted in men who have sex with men and transgender people, among whom HIV and consequently AIDS are most common; a complementary study in women is also ongoing.
Clinical research conducted in many countries in North America, South America and Europe is intended to evaluate HIV vaccine efficacy in people from different regions and thereby develop a safe and protective HIV vaccine.
Different HIV subtypes may predominate in different geographical regions worldwide. Among these subtypes, Clade C HIV is common in southern Africa, where the complementary phase 2 study "Imbokodo" is being conducted; Clade B predominates in Europe and America, where the phase-3 study "Mosaico" will take place. These are investigational vaccines based on "mosaic" immunogens from multiple mosaic subtypes, designed to stimulate immune responses against various common HIV strains.
The Mosaico study is viewed as an important step toward developing a safe and effective HIV vaccine for high-risk groups who could benefit greatly from a preventive HIV vaccine and for people worldwide.
Why are developments in chlamydia and HIV vaccines important?
A strong vaccine is needed that will be effective both in preventing chlamydia infection, whose incidence worldwide rises every year and whose prevention has not been successful, and against its prolonged, recurrent infections. Although AIDS is more common in groups at high risk of transmission, it is a serious disease affecting millions of people for which complete treatment has not yet been achieved. Vaccines developed against these diseases may make protective, boostable immunity against the causative agents of chlamydia and AIDS possible.
Sources
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
The Lancet Infectious Diseases, 12 August 2019.
2. NIH and partners to launch HIV vaccine efficacy trial in the Americas and Europe, The National Institutes of Health, July 15, 2019.
3. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2017; Chlamydia
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.